Form 4: Theodore Leonsis Increases Stake in Tempus AI

Director Theodore Leonsis received 5,913 restricted stock units, increasing his total beneficial ownership to over 88,000 shares.

Summary

• Theodore Leonsis, a Director at Tempus AI, Inc., was granted 5,913 Class A Common Stock units on May 21, 2026.
• The acquisition was a grant of Restricted Stock Units (RSUs) with a conversion price of $0.
• Following the transaction, the reporting person directly owns 21,424 shares.
• An additional 66,756 shares are held indirectly through the Theodore J. Leonsis Revocable Trust.
• The RSUs are scheduled to vest in full on May 21, 2027, or the date of the 2027 annual meeting, whichever is earlier.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine but positive signal of insider commitment and alignment with the company's future performance.

Positives

• Strengthens insider alignment with shareholder interests through equity-based compensation.
• Significant indirect ownership through a revocable trust indicates a long-term investment perspective.
• No shares were sold in this transaction, maintaining the director's net exposure to the company.

Negatives

• The grant represents potential future dilution of Class A Common Stock.
• The value of the compensation is tied to stock price performance, which may be volatile.

Risks

• Vesting is contingent upon continuous service through May 2027.
• The actual realized value of the RSUs depends on the market price at the time of vesting and subsequent sale.

Future Outlook

The granted RSUs will vest in full in May 2027, provided the director remains in continuous service with the company.

Management Comments

• The RSUs will vest in full on the earlier of the date of the 2027 annual meeting or May 21, 2027.

Industry Context

StockSavvy.ai notes that Tempus AI continues to utilize equity-heavy compensation for its leadership, a common trait among AI-driven healthcare companies looking to preserve cash while incentivizing long-term growth.

Comparison to Industry Standards

• Director equity grants at Tempus AI are comparable in structure to those at peers like Schrodinger, Inc. and Guardant Health.
• The one-year cliff vesting schedule is the industry standard for non-employee director compensation.

Corporate Governance

Related Party Transactions

• The grant of RSUs to a director constitutes a standard related-party compensation arrangement.

Stakeholder Impact

• Shareholders may see this as a sign of board stability and confidence.
• Minor potential dilution for existing shareholders upon vesting of the RSUs.

Next Steps

• Vesting of 5,913 RSUs on or before May 21, 2027.

Key Dates

Recommendation

This transaction involves a standard equity grant to a board member, which is a routine part of corporate governance and does not provide new material information regarding financial performance or market position.

Keywords

Tempus AI, TEM, Theodore Leonsis, Insider Trading, Form 4, Restricted Stock Units, Director Compensation, Class A Common Stock